|
Schirdewan博士的引述的參考文獻: + J3 U- O& w8 i8 d
% F; `8 X6 A6 A. ~' P; I
Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009.
! Z2 }' p6 A" K$ ~! g$ \: p( I) {. [" {8 Z6 [2 ~3 b
Daubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008
w5 q/ ]" |# \2 t
+ E) o( `5 w, O' KRicci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010. 8 E1 w+ W9 T, i) }
6 C% y& F% Z; M; {4 ]( ^關於BIOTRONIK SE & Co. KG
& g2 W& \& x! |9 \6 m$ r; |. y" e3 D4 @: m; a9 J* M+ c1 |8 `
BIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|